Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms
Authors:
- Danijela LekovicDLDanijela Lekovic
- Jelena IvanovicJIJelena Ivanovic
- Tatjana TerzicTatjana Terzic
- Maja Perunicic JovanovicMJMaja Perunicic Jovanovic
- Marija Dencic FeketeMFMarija Dencic Fekete
- Jelica JovanovicJJJelica Jovanovic
- Isidora ArsenovicIAIsidora Arsenovic
- Vojin VukovicVVVojin Vukovic
- Jelena BilaJelena Bila
- Andrija BogdanovicABAndrija Bogdanovic
- Darko AnticDADarko Antic
Open Access
- 21 March 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (6) , 1816
Abstract
Background: The occurrence of myeloproliferative neoplasms (MPNs) that evolve into each other is well-described, as is this occurrence of lymphoproliferative neoplasms (LPNs). However, less is known about rare MPN/LPN coexistence, and the aim of our study was to analyze charachteristics of these patients after long term follow-up. Methods: Fourteen patients with MPN/LPN coexistence were diagnosed and treated according to guidelines at a single university center across two decades. Results: The overall median age was 53 years (22–69). MPNs patients with subsequent LPNs had a shorter period of second malignancy development and a more aggressive course of LPN, which can cause fatal outcomes. Polycythemia vera and chronic lymphocytic leukemia were most commonly associated (36%). The JAK2V617F mutation had 2/3 and cytogenetic abnormalities occurred in 1/3 of patients. MPN/LPN coexistence cases had significantly higher thrombotic potential (42.8%) and a higher third malignancy accruement frequency (21.4%) versus those without such malignancies. Conclusions: Considering the younger ages at MPN diagnosis, it is recommended to check regularly for blood lymphocytosis or lymphadenopathy occurrences and organomegaly progression faster than expected for MPN, with the aim of timely LPN diagnoses. The presence of molecular-cytogenetic abnormalities in a majority of patients indicate possible genetic instability and increased risk of development of multiple neoplasms, thus elevating thrombotic risk.Keywords
This publication has 25 references indexed in Scilit:
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Myeloproliferative and lymphoproliferative disorders: State of the artHematological Oncology, 2020
- Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyLeukemia, 2019
- Ruxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasmsAmerican Journal of Hematology, 2019
- Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patientsLeukemia, 2018
- Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic reviewAmerican Journal of Hematology, 2018
- The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experienceAmerican Journal of Hematology, 2011
- Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agentBlood Cancer Journal, 2011
- JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)Leukemia Research, 2009
- Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?Leukemia Research, 2009